ACRS Average Annual Return 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into ACRS


Also see:
ACRS stock yearly return 2015
ACRS stock yearly return 2016
ACRS stock yearly return 2017
ACRS stock yearly return 2018
ACRS stock yearly return 2019
ACRS stock yearly return 2020
ACRS stock yearly return 2021
ACRS YTD return
Compare ACRS average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 10/07/2015
End date: 01/27/2022
Start price/share: $11.05
End price/share: $10.10
Dividends collected/share: $0.00
Total return: -8.60%
ACRS Average Annual Return: -1.41%
Starting investment: $10,000.00
Ending investment: $9,142.63
Years: 6.31


ACRS average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing drug candidates for immuno-inflammatory diseases. Co.'s pipeline of drug candidates that Co. is developing includes: ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; and ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, for the treatment of moderate to severe atopic dermatitis. Co. is also developing ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, as a potential treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases. The ACRS average annual return since 2015 is shown above.

The Average Annual Return on the ACRS average annual return since 2015 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether ACRS average annual return since 2015 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the ACRS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree ACRS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Aclaris Therapeutics (ACRS) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

ACRX Average Annual Return
ACST Average Annual Return
ACXP Average Annual Return
ADGI Average Annual Return
ADIL Average Annual Return
ADMA Average Annual Return
ADMP Average Annual Return
ADPT Average Annual Return
ADTX Average Annual Return
ADUS Average Annual Return
More Healthcare companies »

 

ACRS Average Annual Return 10 Years | www.AverageAnnualReturn.com | Copyright © 2021 - 2022, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.